First Reliance Bancshares Inc. (FSRL) Q4 Earnings Meet Estimates
https://www.zacks.com/stock/news/2216562/first-reliance-bancshares-inc-fsrl-q4-earnings-meet-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2216562
Jan 26, 2024 - First Reliance Bancshares Inc. (FSRL) delivered earnings and revenue surprises of 0% and 10.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Boeing CEO meets with lawmakers as 737 Max 9 scrutiny builds
https://www.cnbc.com/2024/01/24/boeing-ceo-meets-with-lawmakers-as-737-max-9-scrutiny-builds.html
Jan 24, 2024 - Boeing's CEO was on Capitol Hill on Wednesday meeting with senators amid the company's 737 Max 9 crisis.
0
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
https://www.zacks.com/stock/news/2214493/ionis-ions-donidalorsen-meets-late-stage-hae-study-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214493
Jan 23, 2024 - Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.
0
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214367
Jan 23, 2024 - Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
0
Big Yields Meet Big Trouble
https://seekingalpha.com/article/4663632-big-yields-meet-big-trouble?source=feed
Jan 18, 2024 - One of the ETFs we love smashing seems to be struggling. Maybe buying yield blindly isn't a great technique. Click here to read more.
0
U.S. Bancorp (USB) Q4 Earnings Meet on Higher Fee Income
https://www.zacks.com/stock/news/2212226/u-s-bancorp-usb-q4-earnings-meet-on-higher-fee-income?cid=CS-ZC-FT-analyst_blog|earnings_article-2212226
Jan 18, 2024 - U.S. Bancorp (USB) meets Q4 earnings estimates on higher fee income and lower provision for credit losses compared with the year-ago quarter.
0
U.S. Bancorp's (USB) Q4 Earnings Meet Estimates, Costs Up
https://www.zacks.com/stock/news/2211682/u-s-bancorp-s-usb-q4-earnings-meet-estimates-costs-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2211682
Jan 17, 2024 - U.S. Bancorp's (USB) Q4 earnings gain from a rise in revenues and an improvement in credit quality. However, higher expenses and lower NII act as headwinds.
0
Prologis (PLD) Q4 FFO Meet Estimates
https://www.zacks.com/stock/news/2211376/prologis-pld-q4-ffo-meet-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2211376
Jan 17, 2024 - Prologis (PLD) delivered FFO and revenue surprises of 0% and 1.62%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal
https://www.zacks.com/stock/news/2207561/novo-nordisk-s-nvo-phase-iii-diabetes-study-meets-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207561
Jan 09, 2024 - Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.
0
Moderna Covid vaccine sales plunge by two-thirds in 2023, but meet company's $6 billion forecast
https://www.cnbc.com/2024/01/08/moderna-covid-vaccine-sales-plunge-in-2023-but-meet-company-forecast.html
Jan 08, 2024 - Moderna's sales show the steep drop in demand for Covid products as cases and public concern about the virus dwindled front their pandemic peaks.
0